Osteosarcoma (OS) is the most common type of primary bone cancer with malignancy, and it arises from malignant mesenchymal cells producing immature bone and/or osteoid. 1,2 Moreover, it ranks second in regard to the cause of death associated with cancer in children and teenagers. 3 Recently, patients with OS exhibiting no distant metastasis have been shown to project a 5-year survival rate of approximately 65%-70%, which could be attributed to surgery combined with chemotherapy, a major strategy implemented for treating OS. 4 However, this rate in patients exhibiting pulmonary metastasis at an early stage is only 20%, in spite of the advances in chemotherapeutics and surgical techniques, as OS exhibits high-grade malignancy, resistance to chemotherapies and aggressive behaviour. 5-7 Over the last two or three decades, only slight progress has been made in establishing robust treatment